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Abstract
Background: One of the major controversies surrounding the metabolic syndrome (MetS) in type
2 diabetes is whether its single components act synergistically as risk factors for atherosclerotic
vascular disease (AVD). We aimed to answer this by evaluating the relationship, and its various
combinations to AVD in comparison to single traits in a population-based study with type 2
diabetes in Germany.
Methods and results: 4020 unselected patients with type 2 diabetes aged 35 – 80 years. MetS
was: diabetes plus ≥ 2 traits of the MetS by AHA/NHBLI definition.
AVD was: history of myocardial infarction and/or coronary revascularization and/or stroke. The
occurrence of AVD in relation to overall MetS/single traits/combinations was presented as OR
(95% CI). Multiple logistic regression, including established cardiovascular risk factors, modeled
their associations.
The prevalence of overall MetS was 74.4% and the OR for AVD was 1.41 (1.12–1.78), which
however was higher for hypertension as single trait (OR 4.76). Different combinations of MetS
presented a wide range of ORs (0.47 to 10.90) and strong sex differences. Some clusters of MetS
including hypertension and low HDL-cholesterol presented a higher risk factor than single traits or
their sum, whereas the others out of 11 possible carried no increased AVD risk. Multiple logistic
regression showed independent association between AVD and overall MetS.
Conclusion: The overall MetS in type 2 diabetes comprises 11 heterogenous clusters of traits.
Overall MetS increases the risk of AVD in type 2 diabetes and individual traits in some clusters with
hypertension and low HDL-cholesterol may act synergistically as risk factors particularly in women.
Background
Type 2 diabetes is associated with a high prevalence of the
metabolic syndrome (MetS) [1-3]. Since type 2 diabetes
(T2DM) is a component of the American Heart Associa-
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tion/National Heart, Lung, and Blood Institute (AHA/
NHBLI) definition of the syndrome, this finding might
not be surprising. The association between diabetes,
hypertension and gout had already been described in
1923 [4]. Already in the first prospective studies on people
with T2DM and the MetS a close association with athero-
sclerotic vascular diseases (AVD) was observed [2,3].
It is commonly recognized that T2DM is associated with
multiple AVD risk factors. However data on the epidemi-
ology of MetS in unselected patients with T2DM are
scarce. The AHA/NHBLI criteria [5] provide a simple tool
for clinical practice that should help to recognize patients
with the MetS. The risk of AVD in T2DM also depends on
other factors such as sex, hypercholesterolemia, smoking
habits and quality of diabetes control. Therefore many
questions remain open about the epidemiology and rele-
vance of the MetS in T2DM in different countries. Recently
Kahn et al [6], in a critical appraisal, have emphasized that
the MetS in T2DM has not been shown so far to have more
predictive power for AVD than its individual components.
With two additional traits to meet the definition of the
MetS, 6 triads of combinations of traits are possible. All
together we can find 11 likely combinations that meet the
diagnosis of MetS in patients with T2DM and they may
carry different risk for AVD. The epidemiology of these
different combinations and their relationship with AVD
in a population with T2DM has not been evaluated so far.
The Diabetes in Germany (DIG) study is a population-
based, prospective, observational study in patients with
T2DM. This report will analyse the following questions in
a large cross-sectional sample:
1) What is the prevalence of the MetS by AHA/NHBLI cri-
teria, its single traits and their combinations in a repre-
sentative German population with T2DM?
2) Is the MetS an independent risk factor for AVD com-
pared to its single components in men and women?
3) What is the AVD risk for different clusters of the MetS?
Research design and methods
Two hundred and thirty eight practices (79 in big cities,
110 in small towns and 49 in rural areas), that represent a
cross section of daily practice diabetes care in Germany,
took part in the study. With respect to the distribution of
sites in the federal states of Germany was found out an
average frequency of 1.7 to 3.5 per 10,000 inhabitants,
with exception of Saxony where the ratio was 16.9 to
10,000 resp. Inclusion criteria were clinical T2DM and age
between 35 and 80 years. Exclusion criteria were: major
cardiovascular event <3 months before entry (myocardial
infarction (MI), stroke, amputation), heart failure
NYHAIV, macro-proteinuria >300 mg/24 h or creatinine
>2 mg/dl, cancer disease <5 years before entry. The partic-
ipating physicians (General Practitioners and Diabetolo-
gists) were asked to include ≥ 10 consecutive patients with
T2DM per site. A total of 4,331 patients were recruited of
whom 311 had to be excluded due to protocol violations;
thus 4,020 were included in the final analysis. Medical
history and drug intake were registered by a standardized
questionnaire. Body mass index (BMI) and blood pres-
sure were measured according to a standard protocol and
all laboratory measurements were done by local laborato-
ries that held a quality control certification. The following
parameters were registered as baseline characteristics: sex,
age, duration of diabetes, current smoking, BMI, waist cir-
cumference, systolic and diastolic blood pressure, fasting
and postprandial blood glucose, HbA1C, total cholesterol,
LDL-cholesterol, HDL-cholesterol, triglycerides, and cre-
atinine. The traits of the MetS were defined based on the
AHA/NHBLI criteria with one modification. Obesity was
defined as BMI ≥ 30 kg/m2 since waist circumference was
not measured routinely. Hypertension was diagnosed if
blood pressure at the time of inclusion was ≥130/85
mmHg and/or the patients were treated with antihyper-
tensive drugs. The same applies for dyslipidemia with
respect to fibrates and nicotinic acid. Statines, however
were not considered as equivalent of dyslipidemia.
We diagnosed triads (6) of the MetS (diabetes plus two
other traits), quartets (4) (diabetes plus 3 other traits) and
a quintet presenting all the 5 traits. Overall MetS was diag-
nosed when T2DM coexisted with ≥ 2 other traits of the
MetS. Cardiovascular events were identified based on the
medical history obtained by the physicians at the partici-
pating sites. The diagnosis of AVD was established if the
following aggregated events were present: MI and/or cor-
onary revascularization and/or stroke. Since the database
did not allow differentiating amputations by cause we did
not include peripheral vascular disease in the calculations
for AVD. The Saxon Ethics Committee approved the study
and informed consent was obtained from all patients.
Statistics
All data were analyzed using statistical software SPSS Ver-
sion 11.5. Baseline characteristics were presented as
means (SD) for continuous variables and frequency for all
categorical variables. The statistical significance of the dif-
ferences by sex was assessed by t-tests or χ2 tests. The prob-
ability in the occurrence of AVD in relation to the MetS, its
single traits and their combinations were estimated as
odds ratio (OR) (95% CI). Binary logistic regression was
used to model the associations of the overall MetS, its sin-
gle traits, their combinations and of major established risk
factors with AVD and the test of interaction by collinearity
diagnostics.Cardiovascular Diabetology 2007, 6:13 http://www.cardiab.com/content/6/1/13
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Results
Baseline characteristics of the patients by sex are given in
table 1. The study subjects had a mean (SD) age of 61.8
(8.1) years and duration of the disease of 8.4 (6.8) years.
Women were significantly older. The percentage of smok-
ers was low (15%) with significantly more smokers
among men. The average BMI was significantly higher in
women. Mean systolic blood pressure was 139 (17) mm/
Hg, diastolic blood pressure was in the normal range (82
(9) mmHg) with no significant sex difference. The quality
of diabetes control was rather good with an average
HbA1C of 7 (1.2)% for both sexes. Males had significantly
higher postprandial glucose levels than females. Average
LDL-cholesterol was 3.2 (1.0) mmol/l with significantly
higher levels in women. Triglycerides (2.2 (1.7) mmol/l)
were significantly higher in men and the same applied to
creatinine. HDL-cholesterol was significantly higher in
women with an overall level of 1.3 (0.4) mmol/l.
With respect to the prevalence of major cardiovascular dis-
eases, 7.6% of the patients reported a previous MI (10.8%
males and 3.8% females) and 4.3% a stroke (4.5% males
and 4.1% females). The frequency of coronary revascular-
ization was high (6.7% total, 9.8% males and 3.1%
females) in relation to the frequency of MI. Coronary
revascularization and MI were 2–3 times more frequent in
males, but there was no significant sex difference for
stroke. According to our definition 15.2% of our patients
had AVD. Males had a significantly higher frequency than
women: 20.0% and 9.8% resp. (p < 0.001).
Elevated blood pressure was by far the most frequent sin-
gle trait of the MetS found in 91.3%. Approximately every
second patient had a BMI of ≥30 kg/m2and more than half
(55.4%) had hypertriglyceridemia. In contrast, the per-
centage of people with low HDL-cholesterol was less than
10%. The only significant sex difference for single traits
found was in the percentage of obesity with 44.4% in men
and 55.9% in women (p < 0.05). Only 2.4% of the
patients had no additional trait of the MetS with no sex
difference. Duration of diabetes had no significant effect
on prevalence of MetS.
The prevalence of different combinations which meet the
diagnosis MetS is presented in table 2. We found in 35.3%
(36.4% for M, 34.1% for F) a triad representing the MetS.
As expected from the high prevalence of hypertension,
obesity and hypertriglyceridemia the triads with these
three components were found in about any second
patient in both sexes (table 2). The frequency of the other
triad clusters was below 10%. The same applies for quar-
tets. Only the quartet including hypertension, hypertrig-
lyceridemia and obesity reached a prevalence of 31.9%
with significantly higher prevalence in women (34.6%)
than in men (29.5%). The frequency of the other 3 quar-
tets was far below 10%. Only 4.4% of the patients
revealed the full set of traits. Overall MetS was diagnosed
in 74.4% with no significant sex difference. A comparison
of the prevalence of MetS by IDF and AHA/NHBLI defini-
tion in 2993 subjects with waist measurement besides
BMI revealed only minor differences for both definitions:
82.6% were diagnosed by IDF criteria without a signifi-
cant sex difference.
The ORs for AVD risk are presented in table 3. Patients
without another trait had a low OR of 0.24 only, what was
significant for males. Elevated blood pressure as compan-
ion increased the OR significantly to 4.22 in males and
7.69 in females. The only other single trait of significance
was low HDL-cholesterol in females (OR 1.74). For triads
meeting the MetS diagnosis it were the clusters with
hypertension representing with the highest risk: OR 4.25
for men in combination with low HDL and 10.90 for
women resp. The OR for the combination with hyperten-
sion plus hypertriglyceridemia and hypertension plus
obesity was in the same range, whereas the triads with two
lipids and obesity except for hypertriglyceridemia plus
low HDL in females did not increase the risk for AVD.
Among the quartets only the combinations including
hypertension plus low HDL-cholesterol in females were
associated with an increased risk (OR 1.90 and 1.92
resp.). The OR for the quintet, present in 4.4% of the
patients again was only significantly increased in women
(OR 2.03). Eventually, the overall MetS representing a
heterogenous mix of 11 clusters meeting the diagnosis
exhibited a significantly increased OR of 1.38 in men and
1.67 in women resp. As illustrated in figure 1 hyperten-
sion and less pronounced low HDL-cholesterol are the
significant contributors to AVD risk whether as single
additive traits or as components of the metabolic syn-
drome. There is no stepwise increase from triads to quin-
tet. Women exhibit a distinctly higher risk if suffering
from the MetS in any combination.
We conducted logistic stepwise regression analysis to
determine the relevance of the MetS as an independent
risk factor for AVD in T2DM in the context of other major
cardiovascular risk factors. We used 2 models; in the first
we included the well-established risk factors: age, sex,
smoking habit and LDL-cholesterol levels along with the
single traits of the MetS. In the second model we consid-
ered the MetS as a whole, independently of the combina-
tion used, along with the above-mentioned established
risk factors. In both models age, male sex, LDL-cholesterol
levels and smoking were independently associated to
AVD. In the first model T2DM with hypertension
remained also independently associated to AVD as a trait
of the MetS, while in the second model the MetS as a
whole showed an independent association with AVD.
There was no significant influence of interaction betweenCardiovascular Diabetology 2007, 6:13 http://www.cardiab.com/content/6/1/13
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the single traits of MetS on AVD. The calculated models
predicted 85.1% in model 1 and 85.0% in model 2 resp of
AVD or non AVD correctly.
Discussion
We found in this large population based study of patients
with T2DM in Germany a prevalence of the overall MetS
Table 1: 
Parameter Total population Males Females
Number 4020 2140 1880
Age (years) a 61.8 (8.1) 61.2 (8.1) 62.2 (8.0)
Diabetes duration (years) 8.4 (6.8) 8.2 (6.9) 8.6 (6.7)
Current smoking (%) c 15.0 18.9 10.5
BMI (kg/m2) a 30.7 (5.2) 30.0 (4.5) 31.6 (5.8)
Blood pressure (mmHg) systolic 139 (17) 139 (17) 140 (18)
- diastolic 82 (9) 82 (9) 82 (9)
Blood glucose (mmol/l) fasting 7.6 (2.5) 7.6 (2.5) 7.5 (2.4)
- postprandialb 9.2 (2.8) 9.3 (2.8) 9.0 (2.7)
HbA1c (%) 7.0 (1.2) 7.0 (1.3) 7.0 (1.2)
Total cholesterol (mmol/l) a 5.5 (1.2) 5.4 (1.2) 5.7 (1.2)
LDL-cholesterol (mmol/l) a 3.2 (1.0) 3.1 (1.0) 3.4 (1.0)
HDL-cholesterol (mmol/l) a 1.3 (0.4) 1.2 (0.3) 1.4 (0.4)
Triglycerides (mmol/l) b 2.2 (1.7) 2.3 (1.8) 2.2 (1.7)
Creatinine (μmol/l) a 82.9 (19.5) 89.2 (18.9) 75.7 (17.6)
Hypertension (%) 91.3 91.3 91.4
Low HDL-cholesterol (%) 9.3 10.0 8.4
Hypertriglyceridaemia (%) 55.4 56.5 54.1
Obesity (%) a 49.8 44.4 55.9
Only diabetes (%) 2.4 2.6 2.2
Antihypertensive therapy (%) 72.9 71.2 74.8
Medical treatment of diabetes (%)
- oral drugs 42.3 44.1 40.4
- insulin treatment 44.8 41.0 44.9
Therapy with statins (%) a 27.9 29.3 26.2
Therapy with fibrates (%) 4.2 4.6 3.8
Baseline characteristics of the DIG population divided by sex. Data are mean (SD) and %. Gender differences a p < 0.05; b p < 0.01; c p < 0.001.
Table 2: 
Phenotype Total population Males Females
DM+HBP+LHDL (%) 9.7 10.6 8.6
DM+HBP+HTG (%) 55.9 57.1 54.6
DM+HBP+Obes (%)a 50.7 45.3 55.6
DM+LHDL+HTG (%) 8.4 8.7 7.9
DM+LHDL+Obes (%) 5.6 5.6 5.6
DM+HTG+Obes (%)a 33.7 31.1 36.6
DM+HBP+LHDL+HTG (%) 7.8 8.3 7.2
DM+HBP+LHDL+Obes (%) 5.3 5.5 5.2
DM+HBP+HTG+Obes (%)a 31.9 29.5 34.6
DM+LHDL+HTG+Obes (%) 4.7 4.8 4.6
DM+HBP+LHDL+HTG+Obes (%) 4.4 4.6 4.2
DM + one trait (%) 20.5 21.5 19.3
DM + two traits (%) 35.3 36.4 34.1
DM + three traits (%)a 27.2 25.1 29.5
Overall MetS (%) 74.4 73.2 75.8
Prevalence of the different phenotypes of MetS in the DIG population by sex.
Sex differences a p < 0.001.Cardiovascular Diabetology 2007, 6:13 http://www.cardiab.com/content/6/1/13
Page 5 of 7
(page number not for citation purposes)
according to AHA/NHBLI criteria of 74.4% with no sex
difference. However, the analysis of the 11 possible com-
binations which meet the diagnosis MetS reveals a striking
heterogeneity in the prevalence of phenotypes and their
ORs as AVD risk factors resp. Furthermore, we observed a
distinct sex difference with respect to ORs for single traits
as well as for all phenotypes of the MetS.
Table 3: 
Phenotype Total population Males Females
DM alone 0.24 (0.09–0.67) 0.23 (0.07–0.75) 0.23 (0.03–1.66)
DM+HBP 4.76 (2.59–8.76) 4.22 (2.13–8.36) 7.69 (1.89–31.36)
DM+LHDL 1.29 (0.97–1.72) 1.05 (0.73–1.52) 1.74 (1.08–2.81)
DM+HTG 1.04 (0.87–1.26) 0.94 (0.74–1.18) 1.23 (0.89–1.70)
DM+Obes 0.95 (0.79–1.13) 0.96 (0.77–1.20) 1.23 (0.89–1.71)
DM+HBP+LHDL 5.67 (2.84–11.31) 4.25 (1.92–9.41) 10.90 (2.51–47.46)
DM+HBP+HTG 5.64 (2.29–13.87) 4.96 (1.80–13.71) 8.78 (1.21–63.91)
DM+HBP+Obes 6.17 (2.51–15.16) 6.11 (2.22–16.85) 9.19 (1.26–66.82)
DM+LHDL+HTG 1.14 (0.82–1.58) 0.85 (0.55–1.31) 1.78 (1.07–2.96)
DM+LHDL+Obes 0.90 (0.59–1.37) 0.54 (0.29–1.01) 1.76 (0.97–3.19)
DM+HTG+Obes 0.96 (0.79–1.17) 0.91 (0.71–1.17) 1.20 (0.86–1.68)
DM+HBP+LHDL+HTG 1.21 (0.87–1.69) 0.90 (0.58–1.39) 1.90 (1.13–3.20)
DM+HBP+LHDL+Obes 0.95 (0.62–1.46) 0.56 (0.30–1.04) 1.92 (1.05–3.50)
DM+HBP+HTG+Obes 1.01 (0.82–1.23) 0.93 (0.72–1.21) 1.29 (0.92–1.79)
DM+LHDL+HTG+Obes 0.86 (0.54–1.38) 0.47 (0.23–0.95) 1.85 (0.97–3.52)
DM+HBP+LHDL+HTG+Obes 0.92 (0.57–1.47) 0.49 (0.24–1.00) 2.03 (1.06–3.87)
Overall MetS 1.41 (1.12–1.78) 1.38 (1.04–1.82) 1.67 (1.08–2.59)
Odds ratios (95% CI) for AVD of different phenotypes of MetS in the DIG population by sex
OR (95% CI) for AVD in the DIG population divided by sex Figure 1
OR (95% CI) for AVD in the DIG population divided by sex. Data are presented for overall MetS, single traits and their combi-
nations of the MetS. Only those combinations with associated AVD events are displayed. The scale of OR was log-transformed.Cardiovascular Diabetology 2007, 6:13 http://www.cardiab.com/content/6/1/13
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The prevalence of overall MetS in DIG is comparable to
other studies with T2DM in Europe, also they use different
definitions [2,7-11] and slightly lower than the prevalence
reported from NHANESIII [1]. Only 2.4% of the patients
had no other trait, what fits well to the other publications
and illustrates the close overlap of T2DM with the compo-
nents of the MetS [1].
As already described in other epidemiological investiga-
tions with T2DM and MetS hypertension was the most fre-
quent co-morbidity with not less than 91.3%, with no sex
difference. In a recently published study triglycerides were
the strongest predictor to indicate the presence of MetS
among patients with type 2 diabetes of a outpatient clinic
[12]. In contrast to the high prevalence of hypertriglyceri-
demia (55.4%) only 9.3% had decreased HDL-cholesterol
levels. The rather high level of HDL-cholesterol may be
explained by the fact that the patients of the DIG study
reached at average HbA1C level of 7% and that 44.8% of
them were receiving insulin treatment, which is known to
increase HDL-cholesterol [13]. Obesity was significantly
more present in women (55.9%) than men (44.4%).
When we compared the prevalence of central obesity diag-
nosed by waist circumference with obesity by BMI we did
not find a large difference in the prevalence. Thus our data
should not be biased by missing waist circumference.
For the first time we present data on the distribution and
prevalence of the 11 possible clusters hidden in the
unspecified diagnosis overall MetS. In the DIG sample
62.5% of the people had two or three additional traits (tri-
ads, quartets) and only 4.4% had a complete set of com-
ponents of MetS. As expected from the high prevalence of
hypertension, hypertriglyceridemia and obesity the preva-
lence of triads with these components was high: 55.9% for
combination with hypertension plus hypertriglyceri-
demia, 50.7% for combination with hypertension plus
obesity and 33.7% for hypertriglyceridemia and obesity as
companions. Among quartets only the combination with
these three traits was of relevance (31.9%). Of notice was
the low frequency of remaining phenotypes with preva-
lences between 4.7 and 9.7%.
Our data on OR for AVD suggest on the first look that the
overall MetS is associated with an increased risk: OR for
men 1.38 and for women 1.67 resp., but the correspond-
ing ORs for hypertension as single trait were 4.22 and 7.69
resp. In the Botnia study the MetS by WHO definition in
patients with T2DM did not increase the AVD mortality
(RR 1.15 CI 0.68–1.94), while some of its individual com-
ponents such as hypertension and albuminuria were
highly significant predictors of cardiovascular events.
Therefore a critical appraisal put a question to the clinical
relevance of MetS [6]. Based on ADA/NHBLI criteria in
T2DM the diagnosis of MetS can be made for 6 triads, 4
quarters and one quintet of components of the MetS. As
shown in tab. 3 and figure 1 the ORs of these 11 pheno-
types vary in a wide range from 0.47 to 10.90 depending
on individual components and sex. Thus the clusters of
the MetS including hypertension and low HDL-choles-
terol are clearly associated with a higher AVD risk than any
single trait or their sum showing OR for these triads of
5.67, 5.64 and 6.17 resp. On the other hand some clusters
in the DIG study revealed ORs below average risk. This
was the case for specified phenotypes if they did not
include hypertension and low HDL-cholesterol as compo-
nents. In a prospective investigation in patients with cor-
onary angiography [14] dyslipidemia and hypertension
were found to be the hard core of MetS. Our investigation
demonstrates that the AVD risk strongly depends on the
individual components which are the basis of MetS diag-
nosis. This varies between study populations depending
on age, sex, race and other factors and for people with and
without diabetes, what may explain discrepancies
between epidemiological studies with MetS as AVD risk
factor. As shown in the DIG study women with single
traits and/or any cluster of the MetS carry at average a
twice higher AVD risk than men.
In the DIG study overall MetS could be confirmed as inde-
pendent AVD risk factor in multiple regression analysis
including established risk factors such as LDL-cholesterol,
age, sex and smoking. The predictive power of this model
was as good as for multivariate analysis taking the single
traits into the model. We did not find a statistical interde-
pendence of the single traits as risk factors. In a prospec-
tive, community-based study, using modified AHA/
NHBLI definition, in patients with T2DM the increase in
the number of traits was associated with higher CVD rates
[15]. Another prospective study in women >65 years with
diabetes concluded that the association between the MetS
and mortality (mainly AVD) was stronger for the overall
syndrome than for each individual component [16].
There are some limitations to our analysis. We made a
cross-sectional evaluation and our results are subject,
therefore, to survival bias. Some of the combinations of
traits were present in a very low number so that the ORs
could not be calculated or resulted no significant. In addi-
tion, the diagnosis of AVD was based on medical history
and information obtained by home physicians without
the participation of an adjudicator committee. On the
other hand, this population sample represents the real-
world scenario of T2DM in Germany.
The metabolic syndrome is not more or less than a con-
cept for an integrated approach to a cluster of metabolic
diseases with hypertension [17]. This study was not
designed to prove the concept. For this prospective studies
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In conclusion the MetS was found to be an independent
risk factor for AVD in the DIG study together with estab-
lished risk factors such as age, sex, LDL-cholesterol and
smoking. The prognostic power was equal to models with
the single trait as categorical variable. Hypertension as sin-
gle variable had a higher AVD risk than overall MetS.
However, triads of the MetS including hypertension and/
or low HDL-cholesterol had twice as high a risk as hyper-
tension alone. There are however other phenotypes of the
MetS with no increased risk. Thus the metabolic syn-
drome comprises heterogenous clusters with respect to
AVD risk. The data of the DIG study support the concept
to focus on multiple risk factor strategy to prevent AVD in
diabetes.
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